The quinonoid anthracycline, doxorubicin (Adriamycin) is a potent anti-neoplastic agent whose clinical use is limited by severe cardiotoxicity. Mitochondrial damage is a major component of this cardiotoxicity, and rival oxidative and non-oxidative mechanisms for inactivation of the electron transport chain have been proposed. Using bovine heart submitochondrial preparations (SMP) we have now found that both oxidative and non-oxidative mechanisms occur in vitro, depending solely on the concentration of doxorubicin employed. Redox cycling of doxorubicin by Complex I of the respiratory chain (which generates doxorubicin semiquinone radicals, 02-H202, and -OH) caused a 70 % decrease in the V1'ax for NADH dehydrogenase during 15 min incubation of SMP, and an 80 % decrease in NADH oxidase activity after 2 h incubation. This inactivation required only 25-50 uM-doxorubicin and represents true oxidative damage, since both NADH (for doxorubicin redox cycling) and oxygen were obligatory participants. The damage appears localized between the NADH dehydrogenase flavin (site of doxorubicin reduction) and iron-sulphur centre N-1. Succinate dehydrogenase, succinate oxidase, and cytochrome c oxidase activities were strongly inhibited by higher doxorubicin concentrations, but this phenomenon did not involve doxorubicin redox cycling (no NADH or oxygen requirement). Doxorubicin concentrations of 0.5 mm were required for 50 decreases in these activities, except for cytochrome c oxidase which was only 3000 inhibited following incubation with even 1.0 mM-doxorubicin. Our results indicate that low concentrations of doxorubicin (50 /IM or less) can catalyse a site-specific oxidative damage to the NADH oxidation pathway. In contrast, ten-fold higher doxorubicin concentrations (or more) are required for non-oxidative inactivation of the electron transport chain; probably via binding to cardiolipin and/or generalized membrane chaotropic effects. The development of agents to block doxorubicin toxicity in vivo will clearly require detailed clinical studies of doxorubicin uptake in the heart.
INTRODUCTION
Doxorubicin (Adriamycin) is an anthracycline antibiotic widely used in the treatment of various human tumours. The usefulness of this drug is, however, limited by significant toxicity; including a potentially lethal cardiomyopathy [1] . At the cellular level, doxorubicin treatment induces distortion and disruption of mitochondrial and sarcoplasmic reticulum membranes [2] . The effects of doxorubicin and related drugs on mitochondrial properties have been extensively studied in vivo and in vitro, although some of the results remain controversial . Studies with cultured cardiac cells have shown that doxorubicin affects both ATP and phosphocreatine levels [9] . At the mitochondrial level, impairment of several bioenergetic functions has been reported [3] [4] [5] [12] [13] [14] 26, 28] .
Doxorubicin has been demonstrated to be able to form an electrostatic complex with cardiolipin, a phospholipid of the mitochondrial inner membrane [12, 24, 26, 29] . Possible mechanisms for toxicity have been proposed on the basis of this interaction, since Complexes I, III and IV are known to require cardiolipin in their environment in order to maintain maximal activity [31] . It has also been shown that doxorubicin can undergo a one-electron reduction leading to the formation of a semiquinone radical species, this reduction being catalysed by the mitochondrial Complex I [6, [18] [19] [20] [21] [22] . The semiquinone radical species can be re-oxidized, by a one-electron transfer to molecular oxygen, to form superoxide anion. Interaction with the NADH dehydrogenase of Complex I may, thus, allow Adriamycin to produce superoxide, hydrogen peroxide and hydroxyl radicals [18] [19] [20] [21] [22] . Such activated oxygen species have been recognized as agents which can damage lipids, nucleic acids and carbohydrates [32] [33] [34] . Recent work has shown that proteins are also targets for oxidative damage, and that oxidatively denatured proteins undergo rapid proteolytic degradation in mitochondria [35, 36] and various cells [35] [36] [37] [38] [39] [40] [41] [42] .
We felt it was important to gain a more complete biochemical understanding of electron transport chain inactivation by doxorubicin. Such studies could have relevance for the reactions of a wide series of quinonoid compounds with mitochondrial enzymes. Of more immediate importance is the problem of doxorubicin clinical toxicity. Several compounds (vitamins E and C, f-carotene, etc.) are being tested as protective agents in vivo, yet we do not know whether oxidative damage (by oxygen radicals and H202) and non-oxidative damage (cardiolipin binding, membrane chaotropic effects) occur independently or synergistically. To begin to answer such questions (the topic is clearly too large to be solved with a single paper) we have attempted to discriminate oxidative damage and non-oxidative damage to cardiac mitochondrial electron transport chains, caused by doxorubicin. Damage has been assessed both in terms of dehydrogenase ( Vax. and K.) and overall oxidase activities. As previously [18] [19] [20] [21] [22] , bovine heart submitochondrial preparations (SMP) have been used because these preparations contain the entire electron transport chain without the complications of outer membrane, inter-membrane space and matrix components. Since oxidative damage requires both a reductant for the electron transport chain (to 'fuel' doxorubicin redox cycling) and oxygen, we have used incubations in the presence or absence of NADH or succinate, under both aerobic and anaerobic conditions, to discriminate between oxidative damage and non-oxidative damage.
EXPERIMENTAL Submitochondrial preparations (SMP)
Bovine heart mitochondria were isolated by the following modification to the method of Smith, procedure 1 [43] . Bovine hearts were sliced, minced and then homogenized in a buffer' consisting of 0.25 M-sucrose, 0.001 M-EDTA, and 0.01 M-Hepes (pH 7.6). The homogenates (200 w/v) were centrifuged at 1600 g and the supernatants were carefully decanted and filtered through a double layer of gauze. The 1600 g pellets were resuspended, centrifuged again, and the supernatants were decanted and filtered through gauze. The two 1600 g filtered supernatants were combined and then centrifuged at 6000 g to produce a mitochondrial pellet. Mitochondrial pellets were washed three times (by centrifugation) and stored overnight at -80 'C. Before sonication, the mitochondria were suspended in 50 mMpotassium phosphate buffer (pH 7.6) and centrifuged at 6000 g. The pellets were resuspended in 50 mM-potassium phosphate buffer (pH 8.6) containing 2 mM-EDTA [44] , at 20 mg of Biuret protein per ml, and sonicated (4 x 40 s bursts) under an argon atmosphere [19, 20] of its low reactivity with activated oxygen species [45] . Small volumes of doxorubicin were added from freshly prepared solutions in water. For anaerobic incubations, the medium was purged with argon, and the sample vials were filled and closed under an argon atmosphere.
Enzyme assays NADH' dehydrogenase activity was assayed spectrophotometrically by the rate of NADH-dependent ferricyanide reduction at 420 nm, as described by Singer [46] . Five ferricyanide concentrations (0.5-1.0 mM) were used to determine each V..ax or Km data point. In one set of experiments ( [20] . To determine if NADH dehydrogenase could be oxidatively damaged by the redox cycling of doxorubicin, we incubated SMP in the presence or absence of 50 4uM-doxorubicin. Fig. 1 shows NADH dehydrogenase activity, as measured by the ferricyanide reduction assay [46] , following, 0, 5, 10, or 15 min of incubation.
In the absence of doxorubicin, NADH dehydrogenase activity was relatively stable for 15 min of incubation without oxidizable substrate, or with succinate as a reductant for the electron transport chain (Fig. l a) . NADH dehydrogenase activity was also stable in the presence of NADH under an atmosphere of argon (Fig. Ia). Prolonged NADH oxidation in an air atmosphere, however, induced a small but consistent decrease in NADH dehydrogenase activity (Fig. la) . Addition of 50 /tM-doxorubicin had little or no effect on NADH dehydrogenase activity during 15 min incubation with succinate, or without oxidizable substrate (Fig. Ib) . In contrast, incubation with both NADH and doxorubicin caused marked decreases in NADH dehydrogenase activity; 30 % loss of activity after 5 min incubation and 700 loss of activity after 15 min incubation. This NADH and doxorubicin-dependent loss of activity was completely prevented by using an atmosphere of argon for incubation (Fig. 1 b) . The results of Fig. 1 demonstrate the kind of synergism between NADH (as electron donor) and doxorubicin (as the redox cycling agent) which one might expect, if damage to the NADH dehydrogenase is caused by active oxygen species. Succinate (and succinate dehydrogenase) do not reduce doxorubicin [18] [19] [20] [21] [22] , and no redox cycling can occur in the absence of an oxidizable substrate for the electron transport chain, or under anaerobic conditions (argon atmosphere).
To further characterize the inactivation of NADH dehydrogenase by doxorubicin and NADH, we tested the effects of various doxorubicin concentrations after 15 min incubations, or with no incubation. No significant decrease in NADH dehydrogenase activity was observed, at any doxorubicin concentration, if SMP were not incubated ( Fig. 2) . Following 15 min incubation, the loss of NADH dehydrogenase activity was maximal at doxorubicin concentrations of 25-50 gM (Fig. 2 ) in good agreement with the Km for 02-generation (50-60 /tMdoxorubicin) previously reported [20] . In Fig. 2 the initial difference between the NADH dehydrogenase activities in the absence of doxorubicin was due to incubation with Fig. 2 . Effects of doxorubicin concentration on NADH dehydrogenase activity SMP were mixed with 2.5 mM-NADH and various concentrations of doxorubicin. Some samples were then incubated for 15 min at 30°C (A) while others were immediately assayed for NADH dehydrogenase activity (l).
The NADH dehydrogenase activity of the incubated samples was measured after 15 min. Incubation conditions and the ferricyanide assay for NADH dehydrogenase activity [46] were as described in the Experimental section and in the legend to Fig. 1. NADH (see Fig. la [48] and appear to reflect altered subunit interactions in the region of the flavin. Addition of doxorubicin had no effect on either V"ax or Km in the DCPIP assay (Table 1) . Since doxorubicin appears to be reduced by the NADH dehydrogenase flavin [18, 19] , it is possible that DCPIP may also be reduced by the flavin or a nearby site. This would imply that doxorubicin may not affect the ability of the NADH dehydrogenase flavin to accept or donate electrons. In any event, the site which is damaged by doxorubicin redox cycling must lie between the DCPIP reduction site and the ferricyanide reduction site, Fe-SN 1 [46, 47] .
From the results of Figs. 1 and 2 and (Fig. 3a) Doxorubicin concentration (pM) Fig. 3 . Effects of doxorubicin concentration on succinate dehydrogenase activity SMP were incubated for 15 min at 30°C with doxorubicin alone (El), or with doxorubicin plus 2.5 mM-NADH (A).
Succinate dehydrogenase V.ax. (a) and Km (b) activities were measured by the PMS-DCPIP assay [46] as described in the Experimental section. Vmiax activities are given as ,tmol of DCPIP reduced min-' mg-', where 1 ,tmol of DCPIP reduced is equivalent to I ,umol of succinate oxidized. Since NADH can directly reduce PMS, samples which had been incubated were first treated with 2 mM-pyruvate and 2 i.u. of lactate dehydrogenase. This procedure effectively oxidized the remaining NADH (1.52 mm as measured by absorbance at 340 nm), as also evidenced by a lack of PMS reduction in samples tested for background reactivity. The pH of the buffered SMP suspensions was not altered by reaction of lactate dehydrogenase with pyruvate and NADH. Also shown in both panels are the results obtained immediately after mixing doxorubicin with SMP (0), i.e. no NADH and no incubation. All incubation conditions were described in the Experimental section.
damage. The same conclusion is reached from analysis of Km data, measured under identical conditions (Fig. 3b) . Km (Fig. 4) . Anaerobic incubation (10000 argon) of SMP with NADH and 50 /tM-doxorubicin also caused little or no decrease in NADH oxidase activity; however, aerobic incubation decreased NADH oxidase activity by approximately 80 in 120 min (Fig. 4) . Although aerobic incubation with NADH alone caused a small (20%) loss of NADH oxidase activity (results not shown), the decline was markedly greater after aerobic incubation with both NADH and doxorubicin than with either agent alone. The slight decrease in NADH oxidase activity induced by aerobic incubation with NADH alone may reflect the small decrease in NADH dehydrogenase activity seen in Fig. 1 (a) . Whether this decline is due to oxygen radicals generated by the electron transport chain [50, 51] , or whether it reflects a direct modification of NADH dehydrogenase by NADH [48] , is not known. The activity of NADH-ubiquinone reductase is, however, thought to be quite sensitive to oxidative inactivation [52] . the first 5 min (reflecting the expected re-activation of this activity [49] NADH oxidase activity declined sharply at doxorubicin concentrations greater than 0.2 mM (Fig. 5) . Results with and without NADH were essentially the same, indicating direct (non-oxidative) effects of doxo- rubicin on components of the respiratory chain (or its lipid environment). More than a 7000 loss of NADH oxidase activity was observed with 1.0 mM-doxorubicin. Interestingly, the decline in oxidase activity required time (15 min incubation) at doxorubicin concentrations below 0.4-0.6 mm, but appeared to be an immediate effect at higher drug concentrations. Succinate oxidase activity underwent re-activation during incubation with NADH, but declined with increasing doxorubicin concentration (Fig. 6 ). In the absence ofNADH, doxorubicin still exerted its inhibitory effects on succinate oxidase activity, although a period of incubation (15 min) appeared necessary at drug concentrations below 0.4-0.5 mm (Fig. 6 ). In contrast with succinate dehydrogenase activity (Fig. 3) , succinate oxidase exhibited only limited re-activation following incubation with doxorubicin alone (Fig. 6) . Thus, the re-activation of the entire oxidase pathway appears to involve more than just the re-activation of the dehydrogenase. At a concentration of 1.0 mM, doxorubicin caused an apparent 750 decrease in maximal succinate oxidase activity, regardless of the addition of NADH or the use of an incubation period.
The experiments of Fig. 6 0 mM-doxorubicin) . When corrected for these artifactual sources of oxygen consumption, cytochrome c oxidase activity was actually found to decrease with increasing doxorubicin concentrations. The maximal loss of activity observed was 38 % at 1.0 mM-doxorubicin (416 + 30, decreased to 259 + 32 nmol 02 *min-1mg of SMP-1), and the use of an incubation period or the presence of NADH had little or no effect (results not shown).
DISCUSSION
Doxorubicin cardiotoxicity clearly involves damage to heart mitochondria [2, 53] and two main causes for this damage have been proposed: (1) oxidative damage by oxygen radicals and H202, generated by redox cycling of doxorubicin with mitochondrial NADH dehydrogenase [6, 15, [18] [19] [20] [21] [22] 54, 55] ; and (2) non-oxidative inactivation of the electron transport chain by formation of electrostatic complexes between doxorubicin and cardiolipin [12, 24, 26, 29] . Our results indicate that oxidative damage requires less than 50 /M-doxorubicin, and is localized to the site of doxorubicin reduction, the NADH dehydrogenase. Such damage leads to a specific decrease in the overall NADH oxidation capacity of the electron transport chain. In contrast, non-oxidative inactivation requires higher doxorubicin concentrations, and affects several components of the electron transport chain.
As measured by the ferricyanide reduction assay [45] , NADH dehydrogenase activity decreased by 70 / following a 15 min incubation of SMP with NADH and 50 /LM-doxorubicin. NADH oxidase activity decreased by 80 % following aerobic incubation with NADH + 50 /tM-doxorubicin for 120 min. These activity losses were dependent upon both NADH (succinate was not effective) and oxygen, and thus qualify as true oxidative damage. Importantly, succinate dehydrogenase, succinate oxidase and cytochrome c oxidase activities were unaffected even by prolonged incubation with doxorubicin at concentrations of 50 ,tM or less.
At concentrations greater than 50/M, doxorubicin caused an NADH-independent and oxygen-independent apparent increase in NADH dehydrogenase activity (ferricyanide assay). This effect indicates a non-oxidative modification of the enzyme or its environment, resulting in improved ferricyanide accessibility (or an additional ferricyanide reduction site). Incubation with more than 50 /tM-doxorubicin also caused significant inactivation of NADH oxidase, succinate dehydrogenase, succinate oxidase and cytochrome c oxidase by a non-oxidative mechanism (no dependence on NADH or succinate). A doxorubicin concentration of approximately 500 ,uM was required for 50 % inactivation of NADH oxidase, succinate dehydrogenase and succinate oxidase, but cytochrome c oxidase activity was only 38 % diminished even with 1.0 mM-doxorubicin. Since doxorubicin binds strongly to cardiolipin [12, 24, 26, 29] , and since cardiolipin is required for normal Complex I, III and IV activities [31] , the NADH oxidase and succinate oxidase impairments may be the result of cardiolipin sequestration by doxorubicin. Alternatively, enzymatic impairments observed at high doxorubicin concentrations may be the result of a generalized chaotropic effect of the drug in the inner mitochondrial membrane [29] . The loss of succinate dehydrogenase (no cardiolipin requirement but severe inactivation) and cytochrome c oxidase Vol. 259 , 1 (cardiolipin requirement but only mild inactivation) activities appear to be good candidates for a generalized chaotropic effect.
Importantly, the concentrations of doxorubicin which we now show cause non-oxidative inactivation ofelectron transport in SMP are similar to those which have been shown to cause inhibition of oxidase activities in intact mitochondria [3, 5, 25, 26] . Lower concentrations of doxorubicin effectively inhibit succinate oxidation in intact mitochondria [13, 14, 26] but this cannot be due to inactivation of the succinate oxidase pathway itself, since no effect is observed in broken mitochondria or SMP [13] . Unfortunately, we have no explanation for the-high doxorubicin sensitivity of cytochrome c oxidase reported by Goormaghtigh et al. [12] . It should be noted, however, that Goormaghtigh et al. [12] measured the oxidation of cytochrome c rather than actual oxygen consumption.
Johnson et al. [56] have reported that heart cells in culture readily accumulate doxorubicin. Treatment of myocytes with 10 /sM-doxorubicin resulted in intracellular concentrations of 2 mm following 30 min incubation. Approximately 50 % of the accumulated drug appeared to be associated with cell membranes, since it was extractable with ethanol [56] . Mitochondrial membranes, which appear to be major targets of doxorubicin toxicity [2, 53] , may achieve particularly high doxorubicin concentrations under such conditions because of the affinity of doxorubicin for cardiolipin [12, 24, 26, 29] . The experiments of Johnson et al. [56] are particularly significant because the concentration of doxorubicin used, 10 /M, closely matches peak plasma concentrations observed in clinical use of the drug [55] .
The results presented indicate that doxorubicin can cause both oxidative damage and non-oxidative damage to heart mitochondria. The relative proportions of each form of damage are determined by the concentration of doxorubicin employed. The cardiac mitochondrial toxicity of doxorubicin in vivo probably involves initial oxidative damage to NADH dehydrogenase, with gradual loss of NADH oxidase activity during prolonged exposure. Other mitochondrial activities may also be diminished by oxidative damage [52] during prolonged and/or repeated exposures to doxorubicin. Reports [57, 58] that vitamin E protects cultured myocytes against doxorubicin toxicity lend further credence to the 'oxidative damage' hypothesis. If experiments with cultured heart cells [56] mirror events in vivo, however (i.e. if myocardial cells can accumulate doxorubicin from the circulation), we must also consider the non-oxidative inactivation of the electron transport chain by doxorubicin. Clinical studies of doxorubicin uptake and elimination in the heart (which may now be performed by non-invasive n.m.r. techniques) will be critical steps in the application of biochemical understanding to human toxicity. The combination of biochemical studies in vitro and pharmacology in vivo should also permit the development of a rational approach to the amelioration or prevention of doxorubicin toxicity.
